Circular RNA encoded MET variant promotes glioblastoma tumorigenesis

Jian Zhong,Xujia Wu,Yixin Gao,Junju Chen,Maolei Zhang,Huangkai Zhou,Jia Yang,Feizhe Xiao,Xuesong Yang,Nunu Huang,Haoyue Qi,Xiuxing Wang,Fan Bai,Yu Shi,Nu Zhang
DOI: https://doi.org/10.1038/s41467-023-40212-1
IF: 16.6
2023-07-25
Nature Communications
Abstract:Activated by its single ligand, hepatocyte growth factor (HGF), the receptor tyrosine kinase MET is pivotal in promoting glioblastoma (GBM) stem cell self-renewal, invasiveness and tumorigenicity. Nevertheless, HGF/MET-targeted therapy has shown limited clinical benefits in GBM patients, suggesting hidden mechanisms of MET signalling in GBM. Here, we show that circular MET RNA (circMET) encodes a 404-amino-acid MET variant (MET404) facilitated by the N 6 -methyladenosine (m 6 A) reader YTHDF2. Genetic ablation of circMET inhibits MET404 expression in mice and attenuates MET signalling. Conversely, MET404 knock-in (KI) plus P53 knock-out (KO) in mouse astrocytes initiates GBM tumorigenesis and shortens the overall survival. MET404 directly interacts with the MET β subunit and forms a constitutively activated MET receptor whose activity does not require HGF stimulation. High MET404 expression predicts poor prognosis in GBM patients, indicating its clinical relevance. Targeting MET404 through a neutralizing antibody or genetic ablation reduces GBM tumorigenicity in vitro and in vivo, and combinatorial benefits are obtained with the addition of a traditional MET inhibitor. Overall, we identify a MET variant that promotes GBM tumorigenicity, offering a potential therapeutic strategy for GBM patients, especially those with MET hyperactivation.
multidisciplinary sciences
What problem does this paper attempt to address?